Breaking News

Cognate Completes Cobra Acquisition

Cobra Biologics has cGMP facilities in the UK and Sweden.

Cognate BioServices, a contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products has completed the acquisition of Cobra Biologics, a CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector.    Existing Cognate shareholder, EW Healthcare Partners and its co-investors led the investment in Cognate and the financing for the acquisition of Cobra, with participation from Medivate Partners.   Wit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters